hrcak mascot   Srce   HID

Izlaganje sa skupa

OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY

Klementina Ružić ; University Psychiatric Clinic Rijeka, Clinical Hospital Centre Rijeka, Rijeka, Croatia
Elizabeta Dadić-Hero ; University Psychiatric Clinic Rijeka, Clinical Hospital Centre Rijeka, Rijeka, Croatia
Duška Petranović ; University Psychiatric Clinic Rijeka, Clinical Hospital Centre Rijeka, Rijeka, Croatia
Paola Medved ; University Psychiatric Clinic Rijeka, Clinical Hospital Centre Rijeka, Rijeka, Croatia

Puni tekst: engleski, pdf (235 KB) str. 119-121 preuzimanja: 1.314* citiraj
APA 6th Edition
Ružić, K., Dadić-Hero, E., Petranović, D. i Medved, P. (2009). OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY. Psychiatria Danubina, 21 (1), 119-121. Preuzeto s https://hrcak.srce.hr/32802
MLA 8th Edition
Ružić, Klementina, et al. "OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY." Psychiatria Danubina, vol. 21, br. 1, 2009, str. 119-121. https://hrcak.srce.hr/32802. Citirano 26.11.2020.
Chicago 17th Edition
Ružić, Klementina, Elizabeta Dadić-Hero, Duška Petranović i Paola Medved. "OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY." Psychiatria Danubina 21, br. 1 (2009): 119-121. https://hrcak.srce.hr/32802
Harvard
Ružić, K., et al. (2009). 'OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY', Psychiatria Danubina, 21(1), str. 119-121. Preuzeto s: https://hrcak.srce.hr/32802 (Datum pristupa: 26.11.2020.)
Vancouver
Ružić K, Dadić-Hero E, Petranović D, Medved P. OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY. Psychiatria Danubina [Internet]. 2009 [pristupljeno 26.11.2020.];21(1):119-121. Dostupno na: https://hrcak.srce.hr/32802
IEEE
K. Ružić, E. Dadić-Hero, D. Petranović i P. Medved, "OLANZAPINE MONOTHERAPY IN A LONG-TERM TREATMENT FOR SCHIZOPHRENIA: CASE STUDY", Psychiatria Danubina, vol.21, br. 1, str. 119-121, 2009. [Online]. Dostupno na: https://hrcak.srce.hr/32802. [Citirano: 26.11.2020.]

Sažetak
A scientific progress, due to the advancements within the pharmacological industry nowdays, is offering an ever increasing number of atypical antipsychotics for schizophrenia treatment. The atypics are gradually taking over the leadership of the more conventional antipsychotics in treating schizophrenia. The advantages of using atypics are fewer instances of side-effects and a good tolerance of the drug, which promotes an adequate and a satisfactory collaboration of the patients during the treatment. The daily practice often shows a polypragmasia within the treatment itself and a less frequent presence of a monotherapy as a way of treatment of
schizophrenia. A question arises asking us, whether these are just a number of some old practices or, in the other hand, some fears and doubts between the clinitians and patients? The answer remanis for us to ponder upon.
The patient diagnosed with paranoid schizophrenia had been treated with a combination of conventional antipsychotics for many years. Eight years back, olanzapine was introduced in a 20 mg daily dose, combined with an anxiolytic, to which he reacted well. He was kept on the same olanzapine dose exclusively, for the past five years. During the treatment, he used to be monitored regularly (laboratory
analyses, body weight) and no side-effects were percieved. He was in a stable remission during the treatment and a good recovery is evident via social functioning and a working ability.

Ključne riječi
paranoid shizophrenia; monotherapy; olanzapine; remission

Hrčak ID: 32802

URI
https://hrcak.srce.hr/32802

Posjeta: 1.559 *